US Patent

US9125939 — Carbostyril derivatives and mood stabilizers for treating mood disorders

Method of Use · Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2026-07-28 · 0y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition that combines a carbostyril derivative, such as aripiprazole, with a mood stabilizer to treat mood disorders.

USPTO Abstract

The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-sero-tonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamaza-pine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1749 — Abilify
U-1749 — Abilify
U-1749 — Abilify
U-1749 — Abilify
U-1749 — Abilify
U-1749 — Abilify
U-1749 — Abilify
U-1749 — Abilify
U-1749 — Abilify
U-1749 — Abilify
U-1749 — Abilify
U-1749 — Abilify
U-1749 — Abilify
U-1749 — Abilify

Patent Metadata

Patent number
US9125939
Jurisdiction
US
Classification
Method of Use
Expires
2026-07-28
Drug substance claim
No
Drug product claim
No
Assignee
Otsuka Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.